Drug Discovery 서비스 시장 규모, 점유율, 성장 및 세계 업계 분석, 지역별 동향 및 예측(2026-2034년)

Growth Factors of drug discovery services Market

The global drug discovery services market was valued at USD 19.76 billion in 2025 and is projected to grow from USD 21.11 billion in 2026 to USD 36.22 billion by 2034, registering a CAGR of 7.0% during the forecast period. North America dominated the market with a 39.62% share in 2025, supported by strong pharmaceutical research, advanced biotechnology infrastructure, and increasing outsourcing of research and development activities.

Drug discovery services play a critical role in helping pharmaceutical and biotechnology companies identify, validate, and optimize drug candidates before clinical development. These services include medicinal chemistry, biology studies, lead optimization, target identification, toxicology, and biomarker discovery. Growing demand for innovative therapies, rising chronic disease prevalence, expanding biotechnology pipelines, and increasing collaboration between contract research organizations (CROs) and pharmaceutical companies continue to drive market growth. The integration of artificial intelligence (AI), automation, and computational biology is further improving research efficiency and reducing drug development timelines.

Market Trends

A major trend transforming the drug discovery services market is the increasing use of artificial intelligence, machine learning, and automation across the drug discovery workflow. AI-powered platforms are accelerating target identification, virtual screening, lead optimization, biomarker discovery, and ADMET prediction while reducing research costs and improving success rates. Automated laboratory systems, cloud-based research platforms, and computational biology tools are enabling CROs to deliver faster and more accurate results. Pharmaceutical companies are increasingly partnering with specialized service providers that offer integrated digital discovery solutions, strengthening long-term outsourcing relationships.

Market Drivers

The growing prevalence of chronic diseases such as cancer, cardiovascular disorders, neurological diseases, and rare genetic disorders is significantly increasing demand for new therapeutic solutions. Pharmaceutical and biotechnology companies are expanding their research pipelines and increasingly outsourcing early-stage drug discovery activities to specialized CROs to reduce development costs and accelerate commercialization.

Growing investments in biotechnology research, personalized medicine, orphan drug development, and precision therapeutics are also supporting market expansion. Rising collaborations between academic institutions, pharmaceutical companies, and CROs continue to strengthen innovation across global drug discovery programs.

Market Restraints

Despite strong growth prospects, the market faces challenges due to the high cost of advanced drug discovery technologies. Modern discovery platforms require significant investments in high-throughput screening systems, cryo-electron microscopy, AI software, laboratory automation, bioinformatics infrastructure, and skilled scientific professionals. These high capital requirements make advanced discovery capabilities less accessible for small biotechnology firms and emerging CROs.

Market Opportunities

Expanding pharmaceutical outsourcing across emerging economies presents significant growth opportunities for the market. Countries such as China and India continue investing heavily in biotechnology infrastructure, research laboratories, and CRO capabilities. Increasing government support for life sciences, lower operational costs, skilled scientific talent, and expanding pharmaceutical manufacturing ecosystems are attracting global outsourcing contracts. Companies offering integrated chemistry, biology, computational modeling, and AI-enabled discovery services are expected to benefit from growing international demand.

Market Challenges

One of the major challenges is the limited availability of highly specialized CROs in several emerging economies. Advanced capabilities such as medicinal chemistry, translational biology, toxicology, computational drug design, and high-throughput screening remain concentrated among relatively few organizations. Maintaining regulatory compliance, data integrity, intellectual property protection, and scientific expertise while scaling global operations also remains challenging for many service providers.

Segmentation Analysis

Based on service type, the chemistry services segment accounted for the largest market share in 2025 due to its extensive use in compound synthesis, medicinal chemistry, analytical chemistry, and lead optimization throughout small-molecule drug development. The biology services segment is projected to witness strong growth owing to increasing demand for in-vitro profiling, toxicology studies, and biomarker research.

Based on discovery phase, lead optimization dominated the market in 2025 as pharmaceutical companies increasingly outsourced integrated chemistry and biology services to improve candidate selection and accelerate development timelines.

By drug type, the small molecules segment held the largest market share owing to continued approvals of small-molecule therapies and growing treatment demand for chronic diseases. The biologics segment is also expected to expand steadily with increasing investment in biologic therapies and biosimilars.

Based on therapeutic area, oncology remained the leading segment in 2025, driven by increasing global cancer incidence, rising oncology clinical research, and expanding precision medicine initiatives. Neurological diseases are expected to witness robust growth due to increasing research into Parkinson's disease, Alzheimer's disease, epilepsy, and other neurological disorders.

By end user, pharmaceutical and biotechnology companies accounted for the largest revenue share in 2025 as these organizations continue outsourcing discovery activities to improve efficiency, reduce costs, and accelerate product development.

Regional Outlook

North America remained the largest regional market, reaching USD 7.83 billion in 2025. The region benefits from a strong pharmaceutical industry, advanced CRO infrastructure, increasing AI adoption, and continuous investment in biotechnology research. The U.S. market is estimated to reach USD 7.46 billion in 2026, maintaining its leadership in outsourced drug discovery services.

Europe is projected to reach USD 5.72 billion in 2026, supported by increasing pharmaceutical R&D investments, expanding biotechnology research, and strong government support for innovation. Germany and the U.K. continue to represent major regional markets.

Asia Pacific is expected to reach USD 5.16 billion in 2026, driven by expanding pharmaceutical manufacturing, increasing healthcare expenditure, government support for biotechnology, and rapid CRO expansion across China and India. China is projected to reach USD 1.80 billion in 2026, while India is estimated at USD 0.97 billion.

Latin America and the Middle East & Africa are expected to witness steady growth due to increasing pharmaceutical research investments, expanding healthcare infrastructure, and growing participation in global clinical research programs.

Competitive Landscape

The global drug discovery services market is highly competitive, with companies focusing on expanding integrated service portfolios, adopting AI-driven research platforms, strengthening global laboratory networks, and pursuing strategic collaborations. Major market participants include Charles River Laboratories, WuXi AppTec, Labcorp, Evotec, Eurofins Scientific, Sygnature, Pharmaron, Aragen Life Sciences, Sai Life Sciences, and Crown Bioscience.

Recent industry developments demonstrate continued investment in artificial intelligence, biologics capabilities, next-generation sequencing, computational chemistry, and strategic acquisitions. Partnerships between CROs and AI technology providers are improving discovery efficiency while enabling pharmaceutical companies to accelerate innovation across multiple therapeutic areas.

Conclusion

The global drug discovery services market is expected to witness sustained growth through 2034, supported by rising pharmaceutical outsourcing, increasing chronic disease burden, expanding biotechnology research, and continuous technological advancements in AI and laboratory automation. With the market expected to increase from USD 19.76 billion in 2025 to USD 21.11 billion in 2026 and further reach USD 36.22 billion by 2034, service providers offering integrated chemistry, biology, computational research, and digital drug discovery capabilities will remain well-positioned to capitalize on growing global demand.

Segmentation By Service Type, Discovery Phase, Drug Type, Therapeutic Area, End User, and Region

By Service Type * Chemistry Services

• Synthetic Chemistry Services
• Analytical Chemistry Services
• Others
• Biology Services
  • In-vitro Profiling Services
  • Toxicology Services
  • Others

By Discovery Phase * Target Identification & Validation

• Hit Identification
• Hit-to-Lead
• Lead Optimization
• Others

By Drug Type * Small Molecules

• Biologics

By Therapeutic Area * Oncology

• Neurological Diseases
• Infectious Diseases
• Cardiovascular Diseases
• Others

By End User * Pharmaceutical & Biotechnological Companies

• Academic & Research Institutes
• Others

By Region * North America (By Service Type, By Discovery Phase, By Drug Type, By Therapeutic Area, By End User, and by Country)

• U.S. (By Drug Type)
• Canada (By Drug Type)
• Europe (By Service Type, By Discovery Phase, By Drug Type, By Therapeutic Area, By End User, and by Country/Sub-region)
  • U.K. (By Drug Type)
  • Germany (By Drug Type)
  • France (By Drug Type)
  • Italy (By Drug Type)
  • Spain (By Drug Type)
  • Scandinavia (By Drug Type)
  • Rest of Europe (By Drug Type)
• Asia Pacific (By Service Type, By Discovery Phase, By Drug Type, By Therapeutic Area, By End User, and by Country/Sub-region)
  • China (By Drug Type)
  • Japan (By Drug Type)
  • India (By Drug Type)
  • Australia (By Drug Type)
  • Southeast Asia (By Drug Type)
  • Rest of Asia Pacific (By Drug Type)
• Latin America (By Service Type, By Discovery Phase, By Drug Type, By Therapeutic Area, By End User, and by Country/Sub-region)
  • Brazil (By Drug Type)
  • Mexico (By Drug Type)
  • Rest of Latin America (By Drug Type)
• Middle East & Africa (By Service Type, By Discovery Phase, By Drug Type, By Therapeutic Area, By End User, and by Country/Sub-region)
  • GCC (By Drug Type)
  • South Africa (By Drug Type)
  • Rest of Middle East & Africa (By Drug Type)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Challenges
• 3.5. Market Trends

4. Key Insights

• 4.1. Prevalence of Key Disorders, Key Countries/Region, 2025
• 4.2. Overview of Healthcare Expenditure, Key Countries, 2025
• 4.3. Overview of R&D Expenditures, Key Players
• 4.4. Key Industry Developments - Mergers, Acquisitions & Partnerships

5. Global Drug Discovery Services Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Service Type
  • 5.1.1. Chemistry Services
    • 5.1.1.1. Synthetic Chemistry Services
    • 5.1.1.2. Analytical Chemistry Services
    • 5.1.1.3. Others
  • 5.1.2. Biology Services
    • 5.1.2.1. In-vitro Profiling Services
    • 5.1.2.2. Toxicology Services
    • 5.1.2.3. Others
• 5.2. Market Analysis, Insights and Forecast - By Discovery Phase
  • 5.2.1. Target Identification & Validation
  • 5.2.2. Hit Identification
  • 5.2.3. Hit-to-Lead
  • 5.2.4. Lead Optimization
  • 5.2.5. Others
• 5.3. Market Analysis, Insights and Forecast - By Drug Type
  • 5.3.1. Small Molecules
  • 5.3.2. Biologics
• 5.4. Market Analysis, Insights and Forecast - By Therapeutic Area
  • 5.4.1. Oncology
  • 5.4.2. Neurological Diseases
  • 5.4.3. Infectious Diseases
  • 5.4.4. Cardiovascular Diseases
  • 5.4.5. Others
• 5.5. Market Analysis, Insights and Forecast - By End User
  • 5.5.1. Pharmaceutical & Biotechnological Companies
  • 5.5.2. Academic & Research Institutes
  • 5.5.3. Others
• 5.6. Market Analysis, Insights and Forecast - By Region
  • 5.6.1. North America
  • 5.6.2. Europe
  • 5.6.3. Asia Pacific
  • 5.6.4. Latin America
  • 5.6.5. Middle East & Africa

6. North America Drug Discovery Services Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Service Type
  • 6.1.1. Chemistry Services
    • 6.1.1.1. Synthetic Chemistry Services
    • 6.1.1.2. Analytical Chemistry Services
    • 6.1.1.3. Others
  • 6.1.2. Biology Services
    • 6.1.2.1. In-vitro Profiling Services
    • 6.1.2.2. Toxicology Services
    • 6.1.2.3. Others
• 6.2. Market Analysis, Insights and Forecast - By Discovery Phase
  • 6.2.1. Target Identification & Validation
  • 6.2.2. Hit Identification
  • 6.2.3. Hit-to-Lead
  • 6.2.4. Lead Optimization
  • 6.2.5. Others
• 6.3. Market Analysis, Insights and Forecast - By Drug Type
  • 6.3.1. Small Molecules
  • 6.3.2. Biologics
• 6.4. Market Analysis, Insights and Forecast - By Therapeutic Area
  • 6.4.1. Oncology
  • 6.4.2. Neurological Diseases
  • 6.4.3. Infectious Diseases
  • 6.4.4. Cardiovascular Diseases
  • 6.4.5. Others
• 6.5. Market Analysis, Insights and Forecast - By End User
  • 6.5.1. Pharmaceutical & Biotechnological Companies
  • 6.5.2. Academic & Research Institutes
  • 6.5.3. Others
• 6.6. Market Analysis, Insights and Forecast - By Country
  • 6.6.1. U.S.
    • 6.6.1.1. By Drug Type
  • 6.6.2. Canada
    • 6.6.2.1. By Drug Type

7. Europe Drug Discovery Services Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Service Type
  • 7.1.1. Chemistry Services
    • 7.1.1.1. Synthetic Chemistry Services
    • 7.1.1.2. Analytical Chemistry Services
    • 7.1.1.3. Others
  • 7.1.2. Biology Services
    • 7.1.2.1. In-vitro Profiling Services
    • 7.1.2.2. Toxicology Services
    • 7.1.2.3. Others
• 7.2. Market Analysis, Insights and Forecast - By Discovery Phase
  • 7.2.1. Target Identification & Validation
  • 7.2.2. Hit Identification
  • 7.2.3. Hit-to-Lead
  • 7.2.4. Lead Optimization
  • 7.2.5. Others
• 7.3. Market Analysis, Insights and Forecast - By Drug Type
  • 7.3.1. Small Molecules
  • 7.3.2. Biologics
• 7.4. Market Analysis, Insights and Forecast - By Therapeutic Area
  • 7.4.1. Oncology
  • 7.4.2. Neurological Diseases
  • 7.4.3. Infectious Diseases
  • 7.4.4. Cardiovascular Diseases
  • 7.4.5. Others
• 7.5. Market Analysis, Insights and Forecast - By End User
  • 7.5.1. Pharmaceutical & Biotechnological Companies
  • 7.5.2. Academic & Research Institutes
  • 7.5.3. Others
• 7.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.6.1. U.K.
    • 7.6.1.1. By Drug Type
  • 7.6.2. Germany
    • 7.6.2.1. By Drug Type
  • 7.6.3. France
    • 7.6.3.1. By Drug Type
  • 7.6.4. Spain
    • 7.6.4.1. By Drug Type
  • 7.6.5. Italy
    • 7.6.5.1. By Drug Type
  • 7.6.6. Scandinavia
    • 7.6.6.1. By Drug Type
  • 7.6.7. Rest of Europe
    • 7.6.7.1. By Drug Type

8. Asia Pacific Drug Discovery Services Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Service Type
  • 8.1.1. Chemistry Services
    • 8.1.1.1. Synthetic Chemistry Services
    • 8.1.1.2. Analytical Chemistry Services
    • 8.1.1.3. Others
  • 8.1.2. Biology Services
    • 8.1.2.1. In-vitro Profiling Services
    • 8.1.2.2. Toxicology Services
    • 8.1.2.3. Others
• 8.2. Market Analysis, Insights and Forecast - By Discovery Phase
  • 8.2.1. Target Identification & Validation
  • 8.2.2. Hit Identification
  • 8.2.3. Hit-to-Lead
  • 8.2.4. Lead Optimization
  • 8.2.5. Others
• 8.3. Market Analysis, Insights and Forecast - By Drug Type
  • 8.3.1. Small Molecules
  • 8.3.2. Biologics
• 8.4. Market Analysis, Insights and Forecast - By Therapeutic Area
  • 8.4.1. Oncology
  • 8.4.2. Neurological Diseases
  • 8.4.3. Infectious Diseases
  • 8.4.4. Cardiovascular Diseases
  • 8.4.5. Others
• 8.5. Market Analysis, Insights and Forecast - By End User
  • 8.5.1. Pharmaceutical & Biotechnological Companies
  • 8.5.2. Academic & Research Institutes
  • 8.5.3. Others
• 8.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.6.1. Japan
    • 8.6.1.1. By Drug Type
  • 8.6.2. Australia
    • 8.6.2.1. By Drug Type
  • 8.6.3. China
    • 8.6.3.1. By Drug Type
  • 8.6.4. India
    • 8.6.4.1. By Drug Type
  • 8.6.5. Southeast Asia
    • 8.6.5.1. By Drug Type
  • 8.6.6. Rest of Asia Pacific
    • 8.6.6.1. By Drug Type

9. Latin America Drug Discovery Services Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Service Type
  • 9.1.1. Chemistry Services
    • 9.1.1.1. Synthetic Chemistry Services
    • 9.1.1.2. Analytical Chemistry Services
    • 9.1.1.3. Others
  • 9.1.2. Biology Services
    • 9.1.2.1. In-vitro Profiling Services
    • 9.1.2.2. Toxicology Services
    • 9.1.2.3. Others
• 9.2. Market Analysis, Insights and Forecast - By Discovery Phase
  • 9.2.1. Target Identification & Validation
  • 9.2.2. Hit Identification
  • 9.2.3. Hit-to-Lead
  • 9.2.4. Lead Optimization
  • 9.2.5. Others
• 9.3. Market Analysis, Insights and Forecast - By Drug Type
  • 9.3.1. Small Molecules
  • 9.3.2. Biologics
• 9.4. Market Analysis, Insights and Forecast - By Therapeutic Area
  • 9.4.1. Oncology
  • 9.4.2. Neurological Diseases
  • 9.4.3. Infectious Diseases
  • 9.4.4. Cardiovascular Diseases
  • 9.4.5. Others
• 9.5. Market Analysis, Insights and Forecast - By End User
  • 9.5.1. Pharmaceutical & Biotechnological Companies
  • 9.5.2. Academic & Research Institutes
  • 9.5.3. Others
• 9.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.6.1. Brazil
    • 9.6.1.1. By Drug Type
  • 9.6.2. Mexico
    • 9.6.2.1. By Drug Type
  • 9.6.3. Rest of Latin America
    • 9.6.3.1. By Drug Type

10. Middle East & Africa Drug Discovery Services Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Service Type
  • 10.1.1. Chemistry Services
    • 10.1.1.1. Synthetic Chemistry Services
    • 10.1.1.2. Analytical Chemistry Services
    • 10.1.1.3. Others
  • 10.1.2. Biology Services
    • 10.1.2.1. In-vitro Profiling Services
    • 10.1.2.2. Toxicology Services
    • 10.1.2.3. Others
• 10.2. Market Analysis, Insights and Forecast - By Discovery Phase
  • 10.2.1. Target Identification & Validation
  • 10.2.2. Hit Identification
  • 10.2.3. Hit-to-Lead
  • 10.2.4. Lead Optimization
  • 10.2.5. Others
• 10.3. Market Analysis, Insights and Forecast - By Drug Type
  • 10.3.1. Small Molecules
  • 10.3.2. Biologics
• 10.4. Market Analysis, Insights and Forecast - By Therapeutic Area
  • 10.4.1. Oncology
  • 10.4.2. Neurological Diseases
  • 10.4.3. Infectious Diseases
  • 10.4.4. Cardiovascular Diseases
  • 10.4.5. Others
• 10.5. Market Analysis, Insights and Forecast - By End User
  • 10.5.1. Pharmaceutical & Biotechnological Companies
  • 10.5.2. Academic & Research Institutes
  • 10.5.3. Others
• 10.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.6.1. GCC
    • 10.6.1.1. By Drug Type
  • 10.6.2. South Africa
    • 10.6.2.1. By Drug Type
  • 10.6.3. Rest of Middle East & Africa
    • 10.6.3.1. By Drug Type

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Charles River Laboratories
  • 11.2.2. WuXi AppTec
  • 11.2.3. Labcorp
  • 11.2.4. Evotec
  • 11.2.5. Eurofins Scientific
  • 11.2.6. Sygnature
  • 11.2.7. Pharmaron
  • 11.2.8. Aragen Life Sciences Ltd.
  • 11.2.9. Sai Life Sciences Limited
  • 11.2.10. Crown Bioscience